@article{f3fb6a2c05484fe98dc44b8e5d87db59,
title = "Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.",
abstract = "Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.",
keywords = "Covid-19, Critically ill, Sarilumab, SARS-Cov-2 infection, Covid-19, Critically ill, Sarilumab, SARS-Cov-2 infection, Covid-19, Critically ill, Sarilumab, SARS-Cov-2 infection",
author = "H Corominas and I Castellv{\'i} and C Diaz-Torn{\'e} and L Matas and {de la}, {Rosa D} and Mangues MA and P Moya and V Pomar and N Benito and E Moga and Sosa NH and J Casademont and P Domingo",
note = "Copyright {\textcopyright} 2021 the Author(s). Published by Wolters Kluwer Health, Inc.",
year = "2021",
month = may,
day = "14",
doi = "10.1097/md.0000000000025923",
language = "Indefinido/desconocido",
volume = "100",
journal = "Medicine",
issn = "1357-3039",
publisher = "Elsevier BV",
number = "19",
}